<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01430091</url>
  </required_header>
  <id_info>
    <org_study_id>13040</org_study_id>
    <secondary_id>H7T-EW-TADQ</secondary_id>
    <nct_id>NCT01430091</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet</brief_title>
  <official_title>Relative Bioavailability of a Prasugrel Paediatric Orally Disintegrating Tablet Formulation Compared to the Tablet in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the clinical tablet formulation of prasugrel taken orally with an orally
      disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel
      active metabolite circulating in the blood for each treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to the Last Measureable Concentration (AUC[0-tlast]) of Prasugrel's Active Metabolite (PRAS-AM)</measure>
    <time_frame>Pre-dose up to 8 hours post-dose after each treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Prasugrel's Active Metabolite (PRAS-AM)</measure>
    <time_frame>Pre-dose up to 8 hours post-dose after each treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Time of Maximum Concentration (Tmax) of Prasugrel's Active Metabolite (PRAS-AM)</measure>
    <time_frame>Pre-dose up to 8 hours post-dose after each treatment</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Prasugrel clinical formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel (ODT) - on tongue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel (ODT) - apple juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue followed by drinking approximately 180 milliliters (ml) apple juice within 1 minute after the tablet finishes disintegration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel (ODT) - chewed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue, but then chewed and swallowed rather than waiting for it to disintegrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel (ODT) - under tongue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 5-mg prasugrel ODT administered orally by placing it under (rather than on top of) the tongue and keeping it there until it disintegrates.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel (clinical formulation)</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Prasugrel clinical formulation</arm_group_label>
    <other_name>LY640315</other_name>
    <other_name>Effient®</other_name>
    <other_name>Efient®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel (Orally Disintegrating Tablet [ODT])</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Prasugrel (ODT) - on tongue</arm_group_label>
    <arm_group_label>Prasugrel (ODT) - apple juice</arm_group_label>
    <arm_group_label>Prasugrel (ODT) - chewed</arm_group_label>
    <arm_group_label>Prasugrel (ODT) - under tongue</arm_group_label>
    <other_name>LY640315</other_name>
    <other_name>Effient®</other_name>
    <other_name>Efient®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males or females, as determined by medical history and physical
             examination

          -  Are either women who are of child-bearing potential, surgically sterilised or defined
             as post-menopausal. Female subjects of child-bearing potential (not surgically
             sterilised between menarche and menopause) must have a negative pregnancy test at the
             time of screening and must be using a reliable method of birth control. These include
             tubal ligation, an intrauterine device which has been in place for at least 3 months,
             the oral contraceptive pill which has been taken, without difficulty, for at least 3
             months, or an approved hormonal implant. Barrier methods alone (condoms or
             diaphragm/cap) are not acceptable, but must be used in conjunction with a chemical
             method, that is, spermicidal gel. A woman is presumed to be post-menopausal if she has
             had amenorrhoea for greater than 12 months alone or amenorrheic for 6 to 12 months and
             has a serum oestradiol concentration &lt;73 picomoles per liter (pmol/L) (20 picograms
             per milliliter [pg/mL]) (not applicable for women on hormone replacement therapy [HRT;
             oestrogen]) and a follicle stimulating hormone (FSH) concentration &gt;40 international
             units per liter (IU/L).

          -  Have clinical laboratory test results within normal reference range for the
             investigator site, or results with acceptable deviations that are judged to be not
             clinically significant by the investigator

          -  Between the body mass index (BMI) of 18.5 and 32.0 kilograms per meter squared
             (kg/m^2), inclusive

          -  Have acceptable blood pressure (BP) and heart rate (HR) (supine) as determined by the
             investigator

          -  Have venous access sufficient to allow blood sampling

          -  Are reliable and willing to make themselves available for the duration of the study,
             and will abide by the research unit policy and procedure and study restrictions

          -  Have given written informed consent approved by Lilly and the Ethical Review Board
             (ERB) governing the site

        Exclusion Criteria:

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, haematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data, as determined by the investigator

          -  Evidence of significant active neuropsychiatric disease

          -  Have a history or presence of significant bleeding disorders, that is, haematemesis,
             melaena, severe or recurrent epistaxis, haemoptysis, haemorrhage, clinically overt
             haematuria, or intracranial haemorrhage

          -  Have a history (within the last 5 years) or presence of gastric ulcers. Previous
             history of duodenal ulcer is acceptable but must have been successfully surgically or
             medically treated with no further evidence of disease in the past 6 months (from
             screening)

          -  Have a personal or family history of coagulation or bleeding disorders or reasonable
             suspicion of vascular malformations, for example, cerebral haemorrhage, aneurysm, or
             premature stroke (cerebrovascular accident &lt;65 years of age)

          -  Have a self-reported history of significant bleeding from trauma (for example,
             prolonged bleeding after tooth extraction)

          -  Are pre-menopausal females with a history or presence of menorrhagia within the last 5
             years (from screening)

          -  Have clinically significant out of range values for prothrombin time (PT), activated
             partial thromboplastin time (APTT), or platelet count at screening

          -  Have repeatedly reported positive results (at least 2 separate samples) on the faecal
             occult blood examination

          -  Have a history of major surgery within 3 months of screening

          -  Have planned surgery within 14 days after the last study day

          -  Have a clinically significant abnormality in fundoscopic examination or petechiae
             examination

          -  Have any other clinically significant abnormality following the investigator's review
             of the prestudy physical examination, electrocardiogram (ECG) and clinical (safety)
             laboratory tests

          -  Regularly use known drugs of abuse and/or show unacceptable positive findings on
             urinary drug screening

          -  Have known allergies or significant hypersensitivity to prasugrel or related drugs, or
             a history of relevant allergic drug reactions of any origin

          -  Have donated blood of more than 500 mL within the previous 1 month before prasugrel
             administration

          -  Show evidence of positive human immunodeficiency virus (HIV) antibodies

          -  Show evidence of positive hepatitis C antibody

          -  Show evidence of positive hepatitis B surface antigen

          -  Have a regular alcohol intake greater than 21 units/week for males or 14 units/week
             for females or are unwilling to comply with the alcohol consumption requirements from
             48 hours prior to the first dose of prasugrel until discharge from the clinical
             research unit (CRU) after the final Pharmacokinetics (PK) sample of Period 5 has been
             taken. One unit of alcohol is equal to 8 g ethanol

          -  Smoke 10 or more cigarettes per day

          -  Use prescription, over the counter or herbal medications that cannot safely be
             discontinued within 14 days prior to prasugrel administration. Exceptions: subjects
             may continue thyroid replacement therapy, HRT (oestrogen), contraceptives and certain
             medications that are inhaled or applied to the skin, eyes, or nose. The influenza
             vaccine may also be administered; however this must be at least 72 hours before any
             prasugrel dose

          -  Use proton pump inhibitors, antacids, or H2 antagonists, which may impact stomach pH

          -  Have participated in a study involving administration of an investigational compound
             within the 30 days prior to prasugrel administration

          -  Have any other condition that, in the opinion of the principal investigator increases
             the risk to the study subject or decreases the likelihood of obtaining reliable
             results from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <results_first_submitted>October 5, 2012</results_first_submitted>
  <results_first_submitted_qc>October 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2012</results_first_posted>
  <last_update_submitted>October 5, 2012</last_update_submitted>
  <last_update_submitted_qc>October 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Participants</title>
          <description>Received 5 milligrams (mg) prasugrel as either the clinical tablet or as an orally disintegrating tablet (ODT).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants</title>
          <description>Total Number of Study Participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to the Last Measureable Concentration (AUC[0-tlast]) of Prasugrel’s Active Metabolite (PRAS-AM)</title>
        <time_frame>Pre-dose up to 8 hours post-dose after each treatment</time_frame>
        <population>Pharmacokinetic analyses were conducted on the full analysis set, which included all data from all randomized participants receiving at least 1 dose of prasugrel.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinical Tablet</title>
            <description>5-milligrams (mg) prasugrel clinical tablet swallowed whole with approximately 180 milliliters (ml) water.</description>
          </group>
          <group group_id="O2">
            <title>ODT on Top of Tongue</title>
            <description>5-mg prasugrel orally disintegrating tablet (ODT) placed on the tongue and allowed to disintegrate, no liquid given.</description>
          </group>
          <group group_id="O3">
            <title>ODT on Top of Tongue With Juice Chaser</title>
            <description>5-mg prasugrel ODT placed on the tongue and allowed to disintegrate, followed by approximately 180 milliliters (ml) apple juice chaser.</description>
          </group>
          <group group_id="O4">
            <title>ODT Chewed and Swallowed</title>
            <description>5-mg prasugrel ODT chewed and swallowed, no liquid given.</description>
          </group>
          <group group_id="O5">
            <title>ODT Placed Under the Tongue</title>
            <description>5-mg prasugrel ODT placed under the tongue and allowed to disintegrate, no liquid given.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to the Last Measureable Concentration (AUC[0-tlast]) of Prasugrel’s Active Metabolite (PRAS-AM)</title>
          <population>Pharmacokinetic analyses were conducted on the full analysis set, which included all data from all randomized participants receiving at least 1 dose of prasugrel.</population>
          <units>nanogram * hour per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="27.0"/>
                    <measurement group_id="O2" value="42.7" spread="25.0"/>
                    <measurement group_id="O3" value="42.3" spread="29"/>
                    <measurement group_id="O4" value="41.0" spread="32"/>
                    <measurement group_id="O5" value="42.0" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of Prasugrel’s Active Metabolite (PRAS-AM)</title>
        <time_frame>Pre-dose up to 8 hours post-dose after each treatment</time_frame>
        <population>Pharmacokinetic analyses were conducted on the full analysis set, which included all data from all randomized participants receiving at least 1 dose of prasugrel.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinical Tablet</title>
            <description>5-milligrams (mg) prasugrel clinical tablet swallowed whole with approximately 180 milliliters (ml) water.</description>
          </group>
          <group group_id="O2">
            <title>ODT on Top of Tongue</title>
            <description>5-mg prasugrel orally disintegrating tablet (ODT) placed on the tongue and allowed to disintegrate, no liquid given.</description>
          </group>
          <group group_id="O3">
            <title>ODT on Top of Tongue With Juice Chaser</title>
            <description>5-mg prasugrel ODT placed on the tongue and allowed to disintegrate, followed by approximately 180 milliliters (ml) apple juice chaser.</description>
          </group>
          <group group_id="O4">
            <title>ODT Chewed and Swallowed</title>
            <description>5-mg prasugrel ODT chewed and swallowed, no liquid given.</description>
          </group>
          <group group_id="O5">
            <title>ODT Placed Under the Tongue</title>
            <description>5-mg prasugrel ODT placed under the tongue and allowed to disintegrate, no liquid given.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of Prasugrel’s Active Metabolite (PRAS-AM)</title>
          <population>Pharmacokinetic analyses were conducted on the full analysis set, which included all data from all randomized participants receiving at least 1 dose of prasugrel.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3" spread="48"/>
                    <measurement group_id="O2" value="47.6" spread="19"/>
                    <measurement group_id="O3" value="32.3" spread="37"/>
                    <measurement group_id="O4" value="38.3" spread="47"/>
                    <measurement group_id="O5" value="41.9" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Time of Maximum Concentration (Tmax) of Prasugrel’s Active Metabolite (PRAS-AM)</title>
        <time_frame>Pre-dose up to 8 hours post-dose after each treatment</time_frame>
        <population>Pharmacokinetic analyses were conducted on the full analysis set, which included all data from all randomized participants receiving at least 1 dose of prasugrel.</population>
        <group_list>
          <group group_id="O1">
            <title>Clinical Tablet</title>
            <description>5-milligrams (mg) prasugrel clinical tablet swallowed whole approximately 180 milliliters (ml) with water.</description>
          </group>
          <group group_id="O2">
            <title>ODT on Top of Tongue</title>
            <description>5-mg prasugrel orally disintegrating table (ODT) placed on the tongue and allowed to disintegrate, no liquid given.</description>
          </group>
          <group group_id="O3">
            <title>ODT on Top of Tongue With Juice Chaser</title>
            <description>5-mg prasugrel ODT placed on the tongue and allowed to disintegrate, followed by approximately 180 milliliters (ml) apple juice chaser.</description>
          </group>
          <group group_id="O4">
            <title>ODT Chewed and Swallowed</title>
            <description>5-mg prasugrel ODT chewed and swallowed, no liquid given.</description>
          </group>
          <group group_id="O5">
            <title>ODT Placed Under the Tongue</title>
            <description>5-mg prasugrel ODT placed under the tongue and allowed to disintegrate, no liquid given.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time of Maximum Concentration (Tmax) of Prasugrel’s Active Metabolite (PRAS-AM)</title>
          <population>Pharmacokinetic analyses were conducted on the full analysis set, which included all data from all randomized participants receiving at least 1 dose of prasugrel.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.25" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.25" upper_limit="2.00"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.25" upper_limit="1.50"/>
                    <measurement group_id="O4" value="0.75" lower_limit="0.25" upper_limit="2.00"/>
                    <measurement group_id="O5" value="0.50" lower_limit="0.25" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clinical Tablet</title>
          <description>5-milligrams (mg) prasugrel clinical tablet swallowed whole with approximately 180 milliliters (ml) water.</description>
        </group>
        <group group_id="E2">
          <title>ODT (Top of Tongue)</title>
          <description>5-mg prasugrel orally disintegrating tablet (ODT) placed on the tongue and allowed to disintegrate, no liquid given.</description>
        </group>
        <group group_id="E3">
          <title>ODT (Juice Chaser)</title>
          <description>5-mg prasugrel ODT placed on the tongue and allowed to disintegrate, followed by approximately 180 milliliters (ml) apple juice chaser.</description>
        </group>
        <group group_id="E4">
          <title>ODT (Chew and Swallow)</title>
          <description>5-mg prasugrel ODT chewed and swallowed, no liquid given.</description>
        </group>
        <group group_id="E5">
          <title>ODT (Under Tongue)</title>
          <description>5-mg prasugrel ODT placed under the tongue and allowed to disintegrate, no liquid given.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

